Health · 1 sources covering this

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment
ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/6ac7484ac1916b39965c011527529f50539e18d8"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Preliminary trial results suggest a path to a safer Alzheimer&#8217;s treatment"></iframe>

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

How 1 sources are covering this

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

More from Health

Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead

Federal Loan Caps Add Barriers — And Likely Debt — for Healthcare Students

Newsom Reverses on Long-Sought Paid Leave Benefit for Teachers in California

Cuts to funds and staffing have slowed the response to the cyclospora outbreak

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Preliminary trial results suggest a path to a safer Alzheimer&#8217;s treatment

More from Health

Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead

Federal Loan Caps Add Barriers — And Likely Debt — for Healthcare Students

Newsom Reverses on Long-Sought Paid Leave Benefit for Teachers in California

Cuts to funds and staffing have slowed the response to the cyclospora outbreak

Reader

Trust & legal

Across the network

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment